Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27852972 | 0.91 | RXRA (0.33) | RXRARXRBRXRGCES2 | |
| SCHEMBL825745 | 0.84 | CES2 (0.46) | RXRARXRBRXRGCES2IDO1 | |
| SCHEMBL4461544 | 0.81 | CES2 (0.48) | RXRARXRBRXRGCES2HDAC3 | |
| SCHEMBL16958624 | 0.78 | GABRA1 (0.37) | — | |
| SCHEMBL435283 | 0.74 | — | — | |
| SCHEMBL15516021 | 0.73 | NOTUM (0.43) | CES2IDO1 | |
| SCHEMBL5724469 | 0.73 | PTGS1 (0.39) | CES2IDO1 | |
| SCHEMBL7662027 | 0.73 | RAPGEF4 (0.41) | CES2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16957508 | 0.73 | RAPGEF4 (0.42) | CES2 | |
| SCHEMBL27650524 | 0.73 | TSHR (0.46) | CES2IDO1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206748-A | PCB electroplating additive and preparation method thereof | 广东利尔化学有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| EP-3547414-B1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| CN-115650926-A | Azole selenone functional reagent and application thereof | 华南农业大学 | 2023-01-31 | — | — | CN | claimed |
| CN-115508298-A | High-sensitivity aqueous singlet oxygen nano probe based on DPBF, preparation method and application | 常州大学 | 2022-12-23 | — | — | CN | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| CN-110577563-B | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2020-09-04 | — | — | CN | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| CN-110577563-A | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2019-12-17 | — | — | CN | claimed |
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| CN-1547584-A | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | — | 2004-11-17 | — | — | CN | claimed |
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2004-09-30 | — | — | US | claimed |
| EP-1401841-A1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2004-03-31 | — | — | EP | claimed |
| WO-2003000699-A1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO[4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2003-01-03 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-5916920-A | CONTROLLING NEUROTRANSMITTER RECPETORS; NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | claimed |
| EP-0774455-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | SULT1E1, CYP4B1, CYP3A4 | RXRA 2193/4885RXRB 2566/4885RXRG 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.